Display options
Cite
Juliusson, G., Hagberg, O., Lazarevic, V., Lorenz, F., Ölander, E., Antunovic, P., ... & Höglund, M. (2019). PS1032 SURVIVAL FROM ACUTE MYELOID LEUKEMIA HAS SINCE 1997 IMPROVED ONLY IN MALES AGED 50–75 YEARS–A SWEDISH POPULATION-BASED STUDY. HemaSphere, 3(S1), 466.
Juliusson, G., et al. "PS1032 SURVIVAL FROM ACUTE MYELOID LEUKEMIA HAS SINCE 1997 IMPROVED ONLY IN MALES AGED 50–75 YEARS–A SWEDISH POPULATION-BASED STUDY." HemaSphere 3.S1 (2019): 466.
Copy Download .nbib Format: MLA
Share it on
Full text links
View full text

G Juliusson, O Hagberg, V Lazarevic, F Lorenz… - …, 2019 - journals.lww.com

PS1032 SURVIVAL FROM ACUTE MYELOID LEUKEMIA HAS SINCE 1997 IMPROVED ONLY IN MALES AGED 50–75 YEARS–A SWEDISH POPULATION-BASED ….

STEM and males

Lazarevic

GSID: CpCIDEs1NtcJ

Excerpt

Background: For AML (excluding APL), there has until recently been no major changes in AML-specific drug therapy, but improvements of supportive care and access to allogeneic transplantation (SCT). Aims: We aimed to analyze changes in survival from AML (non-APL) over the period 1997–2016, and to identify and characterize patient subsets with greater improvement. Methods: Data from all Swedish AML-patients, diagnosed from 1997 and reported in the Swedish AML Registry (n= 7708), including type of AML, diagnostic findings …

Similar articles